S. 1999

Medicare Prescription Drug Price Reduction Act

Latest
        [Congressional Bills 108th Congress]
[From the U.S. Government Publishing Office]
[S. 1999 Introduced in Senate (IS)]

108th CONGRESS
1st Session
S. 1999

To amend part D of title XVIII of the Social Security Act, as added by
the Medicare Prescription Drug, Improvement, and Modernization Act of
2003, to provide for negotiation of fair prices for Medicare
prescription drugs.

_______________________________________________________________________

IN THE SENATE OF THE UNITED STATES

December 9, 2003

Mr. Daschle (for himself, Ms. Stabenow, Mr. Graham of Florida, Mr.
Kennedy, Mr. Pryor, Mr. Dorgan, Mrs. Boxer, Mr. Lautenberg, Mr.
Bingaman, Ms. Mikulski, Mr. Johnson, Mr. Schumer, Mr. Kohl, Ms.
Cantwell, and Mr. Rockefeller) introduced the following bill; which was
read twice and referred to the Committee on Finance

_______________________________________________________________________

A BILL

To amend part D of title XVIII of the Social Security Act, as added by
the Medicare Prescription Drug, Improvement, and Modernization Act of
2003, to provide for negotiation of fair prices for Medicare
prescription drugs.

Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the ``Medicare Prescription Drug Price
Reduction Act''.

SEC. 2. NEGOTIATING FAIR PRICES FOR MEDICARE PRESCRIPTION DRUGS.

Section 1860D-11 of the Social Security Act, as added by section
101(a) of the Medicare Prescription Drug, Improvement, and
Modernization Act of 2003, is amended by striking subsection (i)
(relating to noninterference) and by inserting the following:
``(i) Authority To Negotiate Prices With Manufacturers.--In order
to ensure that beneficiaries enrolled under prescription drug plans and
MA-PD plans pay the lowest possible price, the Secretary shall have
authority similar to that of other Federal entities that purchase
prescription drugs in bulk to negotiate contracts with manufacturers of
covered part D drugs, consistent with the requirements and in
furtherance of the goals of providing quality care and containing costs
under this part.''.
<all>